美国新泽西州 – 2023年7月24日,SPAC公司(特殊目的收购公司)Keen Vision Acquisition Corporation(简称“KVAC”)在美国纳斯达克上市,股票代码为KVACU。据悉,该SPAC的每单位发行价为10美元(包括一股普通股和一份认股权证),募资金额接近1.5亿美元。KVAC是2023年首支提交IPO申请的SPAC公司,也是2023年迄今在美国首次发行新股募资金额最高的亚洲背景(中国香港发起人)SPAC公司。KVAC此次上市反应非常热烈,路演前已获许多基金跟踪,结果将近超额认购3倍。

New Jersey – July 24, 2023 – Special purpose acquisition company (SPAC) Keen Vision Acquisition Corporation (KVAC) began trading on the Nasdaq in the United States (US) with ticker symbol KVACU. It is reported that the offering price per unit of the SPAC is US$10 (including one ordinary share and one redeemable warrant), raising approximately US$150 million in trust funds. KVAC is the first SPAC company to submit an initial public offering (IPO) application in 2023 and currently holds the record for the highest fundraising amount amongst Asia-based (with Hong Kong, China background) SPACs listed in the US in 2023 to date. There was high level of interest for KVAC’s IPO, with institutional funds following KVAC even before roadshow marketing started, resulting in approximately 3 times of over-subscription.

KVAC合并业务重心将专注于全球的农业、生物科技和消费品领域的优质企业,并将依据可持续发展和ESG标准对企业进行评估。

KVAC’s primary focus for business combination will be on high-quality enterprises in the global agriculture, biotechnology, and consumer goods sectors. KVAC will evaluate these businesses based on sustainability, and environmental, social, and governance (ESG) standards. 

当地时间7月25日,是KVAC首个上市交易日,其表现可谓是十分引人注目。仅在首个交易日的前两个小时,其交易量就超过了首次公开发行(IPO)的规模,当天成交额高达1.61亿美元。

New Jersey – July 25, 2023 – KVAC’s performance on its first day of trading was truly exceptional. Within the first two hours of trading, its trading volume surpassed the size of its initial public offering (IPO), with a total turnover reaching an impressive US$161 million for the day.

招股书显示,KVC Sponsor LLC为KVAC的发起人,该公司系由Keen Vision Capital (“凯华资本”)和王干文先生(Jason Wong)共同设立。凯华资本是一家由黄嘉俊先生(Kenneth KC Wong)创立并管理的单一家族办公室,专注于私募股权投资。黄嘉俊先生同时是KVAC的董事局主席及CEO。

According to the prospectus, KVC Sponsor LLC is the sponsor of KVAC, jointly established by Keen Vision Capital (KVC) and Mr. Jason Wong. KVC is a single-family office founded and managed by Mr. Kenneth KC Wong, specializing in private equity investments; and Mr. Jason Wong has been practicing private equity for several decades. Mr. Kenneth KC Wong serves as KVAC’s Chairman and CEO.

黄嘉俊先生  Kenneth KC Wong

黄嘉俊先生现为凯华资本主席兼行政总裁。他在投资、并购和融资方面拥有逾25年经验,尤其在农业、生物科技和消费品等领域具有丰富的项目投资和退出经验。其领导的凯华资本所投资的部分企业已成长为行业中的佼佼者,有些更成为其行业内规模最大上市案例。黄嘉俊先生是市场上为数不多拥有全方位经验(营运、融资、投资、退出、收购合并)的投资专家。

Mr. Kenneth KC Wong currently also serves as the KVC’s Chairman and CEO. With over 25 years of experience in investment, merger and acquisition (M&A), and fundraising, he possesses extensive investment and exit experiences especially in the sectors of agriculture, biotechnology and consumer goods. Some of the enterprises invested in by KVC became leaders in their respective industries, with several even achieving the largest IPOs in their sectors. He is one of the few investment experts in the market with all-round experience in operations, fundraising, investment, exit and M&A. 

 

左:黄嘉俊先生(Kenneth KC Wong)      右:王干文先生(Jason Wong)

王干文先生  Jason Wong

王干文先生现为诺圻资本创始人及主席。他自2014年起便参与美国SPAC的发起,是亚洲地区最早参与发起SPAC上市的人士之一。截至目前,王干文先生所参与发起的SPAC数量在亚洲地区处于领先地位,且其中数家SPAC已成功完成de-SPAC,故媒体(包括彭博社)及业内称其为“亚洲SPAC教父”。他参与的SPAC在 2015年被国际并购杂志评为2014最佳上市项目,他还发起了首家并购美国本土生物制药企业的亚洲背景SPAC。香港SPAC上市制度落地后,王干文先生也参与发起了首批香港SPAC,他是首个提出将香港打造成为“亚洲SPAC中心”的倡导者。王干文先生还是多家中外知名财经媒体的特邀嘉宾和专栏作者。王干文先生领导的诺圻资本团队是目前市场上为数不多兼具美国和香港SPAC发起和成功de-SPAC经验的亚洲团队之一。

Mr. Jason Wong currently serves as the founder and Chairman of Norwich Capital. Since 2014, Mr. Jason Wong has been involved in the initiation of SPACs in the US and is one of the earliest participants from Asia in SPAC listings. As of now, Mr. Jason Wong has been a leading figure in the number of SPACs initiated in the Asia region, with several of them successfully completing de-SPAC processes, earning him the title of “Asia’s SPAC Godfather” in the media (including Bloomberg) and the SPAC industry. One of the SPACs he was involved in was awarded the Best IPO Project in 2014 by an international M&A magazine, and he initiated the first Asia-based SPAC to acquire a domestic US biopharmaceutical company. After the introduction of SPAC listing regulations in Hong Kong, Mr. Jason Wong also participated in the initiation of the first batch of Hong Kong SPACs, making him an advocate for transforming Hong Kong into the “Asian SPAC hub”. Mr. Jason Wong is also a special guest and columnist for several well-known financial and economic media outlets. Norwich Capital, as led by Mr. Jason Wong, is one of the very few Asian teams in the market with successful track records in both US and Hong Kong SPAC initiation and de-SPAC processes.